Table 1.
Patient | Age (yr) | Primary treatment | Initial tumour stage | Gleason score | Hormonal therapy after primary treatment | Radio-therapy after primary treatment | PSA initial (ng/ml) | PSA1 (ng/ml) | [11C] choline PET/CT | [18F]fluoro-ethylcholine PET/CT | PET/CT positive LN | PSA2 (ng/ml) | Follow-up (month) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 61 | RRP + PLND | pT3a pN0 M0 R0 | 3 + 4 | - | - | 4.13 | 0.92 | + | - | 1 | 0.22 | 79 |
2 | 59 | RRP + PLND | pT2c pN0 M0 R0 | 4 + 3 | + | - | 26.7 | 4.09 | + | - | 1 | <0.01 | 83 |
3 | 64 | RRP + PLND | pT3a pN1 M0 R0 | 4 + 3 | - | - | 16.0 | 2.45 | + | - | 1 | <0.01 | 72 |
4 | 68 | RRP | pT3a pNx M0 R0 | - | - | + | 9.9 | 1.64 | - | + | 1 | <0.01 | 37 |
5 | 78 | RRP + PLND | pT3b pN0 M0 R0 | 3 + 4 | - | - | 3.2 | 1.62 | + | - | 1 | 2.7 | 27 |
6 | 59 | RRP + PLND | pT3a pN0 M0 R0 | 4 + 3 | + | - | 7.6 | 4.51 | + | - | 1 | 1.5 | 6 |
7 | 49 | RRP + PLND | pT3b pN0 M0 R0 | 4 + 5 | - | - | 4.0 | 0.67 | + | - | 1 | 0.03 | 5 |
8 | 61 | RRP + PLND | pT3a pN0 M0 R0 | 5 + 5 | + | + | NA | 9.55 | + | - | 3 | 54.46 | 12 |
9 | 53 | RRP + PLND | pT3a pN0 M0 R1 | 4 + 4 | - | + | 36.0 | 3.54 | - | + | 1 | 0.4 | 7 |
10 | 75 | RRP + PLND | pT3a pN0 M0 R1 | 4 + 3 | - | + | 5.94 | 3.77 | + | - | 1 | 10.3 | 2 |
11 | 75 | RRP + PLND | pT3a pN0 M0 R0 | 3 + 3 | - | + | 7.14 | 0.94 | - | + | 1 | 0.01 | 10 |
12 | 55 | RRP + PLND | pT3b pN1 M0 R0 | 4 + 3 | - | - | 5.08 | 0.5 | + | - | 2 | no histologically confirmed LNM | |
13 | 64 | RRP + PLND | pT3a pN0 M0 R1 | - | - | + | 8.21 | 1.23 | + | - | 1 | no histologically confirmed LNM | |
Median | 61 | 1.64 | 1 |
RRP = radical retropubic prostatectomy; PLND = pelvic lymph node dissection; PSA initial = PSA at primary diagnosis; PSA1 = PSA at time of PET/CT diagnosis; PSA2 = PSA after resection of lymph node metastases; LNM = lymph node metastases. NA = not available.